Also known as M281.
Exit interviews found 96% reported mouth dryness and linked symptom relief to better daily functioning; Phase 2 saliva gains with nipocalimab helped shape the Phase 3 DAFFODIL design.
Phase 2 data show FcRn blocker nipocalimab reduced SLE activity versus placebo, with larger benefit in autoantibody‑positive patients and no new safety signals.
FDA granted Priority Review to nipocalimab sBLA for warm autoimmune hemolytic anemia after Phase 2/3 ENERGY showed durable hemoglobin responses and fatigue improvement; review ~6 months.